About US
Contact us
-
Roche looks to earn even more from Perjeta with EU nodRoche ($RHHBY) breast cancer drug Herceptin has been so effective that it earns the Swiss drugmaker boatloads of money. And Roche today tightened its lock on the breast cancer treatment market, and i2012/12/17
-
Ariad's potential blockbuster Iclusig gets early FDA OKAfter fast-tracking it, the FDA approved Ariad Pharmaceuticals' ($ARIA) closely watched leukemia drug ponatinib today, a product that analysts say could generate blockbuster sales. The FDA said Iclus2012/12/17
-
AstraZeneca, Lilly feeling real pain in race for arthritis drugsThe supercharged race to get new treatments into the lucrative market for treating rheumatoid arthritis (RA) appeared to thin considerably today as one contender dropped a study and another's drug cam2012/12/14
-
With FDA drug app in, Lundbeck gets much-needed good newsThere was a glimmer of good news today for Lundbeck, which has been slashing its payroll and its earnings projections as it wrestles with the patent loss of blockbuster Lexapro. The FDA has accepted2012/12/14
-
Gilead caps 2012 roll by bagging cancer drugmakerGilead Sciences ($GILD) has seen its stock price grow more than 80% this year on a number of positive developments. Already a leader in medications for HIV, it got a new combo med approved a few mont2012/12/13
-
AOP Orphan Pharmaceuticals Reports Positive Phase II Data of Novel Mono-Pegylated Interferon Alpha 2b for Treatment of Polycythemia Vera (PV)AOP Orphan Pharmaceuticals AG (AOP Orphan) today announced that based on promising phase II data it will initiate a phase III trial to support European Marketing Authorization of a novel mono-pegylate2012/12/13
-
India kills Merck patent in ongoing campaignIndia has done it again, revoking another patent from a Big Pharma player on the grounds that it shows no innovation. This time it nailed a Merck & Co. ($MRK) asthma drug, the Business Standard r2012/12/12
-
Levin lays out 4-year plan to turn Teva into a brandTeva Pharmaceuticals ($TEVA) has money in the bank, drugs in the pipeline and big plans for the future. Given those assets and four more years, CEO Jeremy Levin told investors on Tuesday they will ha2012/12/12
-
Pharmaceutical regulatory affairs teams continue to increase budgetsPharmaceutical companies have continued to boost the budgets allocated to their regulatory affairs teams, despite making overall spending cuts, a study suggests. Cutting Edge Information's latest stu2012/12/11
-
Merck wins back $500K in retaliation lawsuitThe courts giveth and the courts taketh away, and how you view those actions depends on which side of a lawsuit you sit on. In a recent ruling by a federal appeals court, Merck & Co. ($MRK) was ha2012/12/11